Stock Yards Bank & Trust Co. Sells 687 Shares of Edwards Lifesciences Co. (NYSE:EW)

Stock Yards Bank & Trust Co. cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 16.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,390 shares of the medical research company’s stock after selling 687 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Edwards Lifesciences were worth $258,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of EW. SG Americas Securities LLC grew its position in Edwards Lifesciences by 4.9% during the 3rd quarter. SG Americas Securities LLC now owns 37,480 shares of the medical research company’s stock worth $2,597,000 after acquiring an additional 1,734 shares during the last quarter. Caprock Group LLC grew its position in Edwards Lifesciences by 4.8% during the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock worth $597,000 after acquiring an additional 392 shares during the last quarter. Oak Thistle LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $700,000. Czech National Bank grew its position in Edwards Lifesciences by 48.1% during the 3rd quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after acquiring an additional 34,487 shares during the last quarter. Finally, Asset Management One Co. Ltd. grew its position in Edwards Lifesciences by 0.5% during the 3rd quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after acquiring an additional 1,622 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research report on Friday, February 2nd. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Royal Bank of Canada increased their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Mizuho increased their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $88.62 on Thursday. The company has a market capitalization of $53.34 billion, a PE ratio of 38.53, a PEG ratio of 4.35 and a beta of 1.05. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $90.23 and its 200 day simple moving average is $78.69.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS. On average, research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.